madman
Super Moderator
* In symptomatic chronic venous disease patients, MPFF 1000 mg once daily and MPFF 500 mg twice daily improve patient compliance, lower limb discomfort, clinical adverse events, and quality of life scores similarly.
Abstract
Background
Micronized purified flavonoid fraction (MPFF) is a widely prescribed and extensively investigated venoactive drug (VAD). The standard dosage for MPFF is 500 mg administered twice daily. However, a new daily dose of 1000 mg has just been introduced.
Objective
This study investigated whether a daily dose of 1000 mg MPFF could be implementedand embraced by the public and still has the same therapeutic effects as conventional pharmaceuticals.
Methods
For this meta-analysis, we searched MEDLINE, Embase, Science of Web, Cochrane, and PubMed databases and forward and backward citations for studies published between database inception and March 2023. Three randomized controlled trials (RCTs) of comparison of different dosages of MPFF to evaluate whether there is a significant difference between them were included, without language or date restrictions. Due to the small sample size of the study included, we conducted a simple sensitivity test using a one-by-one exclusion method, and the results showed that the study did not affect the final consolidation conclusion. The quality of the evidence was assessed using the Cochrane risk-of-bias tool.
Results
Out of 232 studies, 99 were eligible and 39 RCTs had data, all with low to moderate bias. Overall, 1924 patients (experimenta lgroup: 967, control group: 957) in 3 RCTs met the criteria. There is no significant difference in patient compliance, efficacy, clinical adverse events, and quality of life scores between MPFF 1000 mg once daily and MPFF 500 mg twice daily (standardized mean difference [SMD]: 0.049 [0.048, 0.145], p=0.321, risk ratio [RR]: 0.981 [0.855, 1.125], p=0.904, andSMD: 0.063 [0.034, 0.160], p=0.203).
Interpretation
In symptomatic chronic venous disease patients, MPFF 1000 mg once daily and MPFF 500 mg twice daily improve patient compliance, lower limb discomfort, clinical adverse events, and quality of life scores similarly. Regular medical care should recommend MPFF 1000 mg daily more often.
Conclusion
This meta-analysis shows that taking MPFF 1000 mg orally once daily and taking it twice daily are both effective in reducing patients’ limb discomfort and improving QoL scores, but there is no significant difference; there also was no significant difference in the occurrence of AEs and patient compliance between the 2 medication regimens. To produce more trustworthy results, more RCTs with longer treatment cycles and comparisons of various dosage forms are required.
Abstract
Background
Micronized purified flavonoid fraction (MPFF) is a widely prescribed and extensively investigated venoactive drug (VAD). The standard dosage for MPFF is 500 mg administered twice daily. However, a new daily dose of 1000 mg has just been introduced.
Objective
This study investigated whether a daily dose of 1000 mg MPFF could be implementedand embraced by the public and still has the same therapeutic effects as conventional pharmaceuticals.
Methods
For this meta-analysis, we searched MEDLINE, Embase, Science of Web, Cochrane, and PubMed databases and forward and backward citations for studies published between database inception and March 2023. Three randomized controlled trials (RCTs) of comparison of different dosages of MPFF to evaluate whether there is a significant difference between them were included, without language or date restrictions. Due to the small sample size of the study included, we conducted a simple sensitivity test using a one-by-one exclusion method, and the results showed that the study did not affect the final consolidation conclusion. The quality of the evidence was assessed using the Cochrane risk-of-bias tool.
Results
Out of 232 studies, 99 were eligible and 39 RCTs had data, all with low to moderate bias. Overall, 1924 patients (experimenta lgroup: 967, control group: 957) in 3 RCTs met the criteria. There is no significant difference in patient compliance, efficacy, clinical adverse events, and quality of life scores between MPFF 1000 mg once daily and MPFF 500 mg twice daily (standardized mean difference [SMD]: 0.049 [0.048, 0.145], p=0.321, risk ratio [RR]: 0.981 [0.855, 1.125], p=0.904, andSMD: 0.063 [0.034, 0.160], p=0.203).
Interpretation
In symptomatic chronic venous disease patients, MPFF 1000 mg once daily and MPFF 500 mg twice daily improve patient compliance, lower limb discomfort, clinical adverse events, and quality of life scores similarly. Regular medical care should recommend MPFF 1000 mg daily more often.
Conclusion
This meta-analysis shows that taking MPFF 1000 mg orally once daily and taking it twice daily are both effective in reducing patients’ limb discomfort and improving QoL scores, but there is no significant difference; there also was no significant difference in the occurrence of AEs and patient compliance between the 2 medication regimens. To produce more trustworthy results, more RCTs with longer treatment cycles and comparisons of various dosage forms are required.
